Physician profile
Lyuba Belitsky
NPI 1205936143
$10,503.83
in general payments reported to CMS, 2019-2025
60 companies · $1,480 in 2025
The $1,480 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,119 · 2020: $1,283 · 2021: $1,940 · 2022: $1,064 · 2023: $1,199 · 2024: $1,419 · 2025: $1,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,066 · Education: $32.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,065.56 |
| Education | $32.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,290.04 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $963.10 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $737.06 | 2019-2025 | Jardiance |
| Amgen INC. | $656.07 | 2019-2025 | Evenity, Prolia, Tepezza |
| Astrazeneca Pharmaceuticals LP | $654.70 | 2019-2024 | Farxiga |
| Abbott Laboratories | $531.43 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Xeris Pharmaceuticals, INC. | $529.82 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $492.69 | 2019-2025 | |
| Abbvie INC. | $391.05 | 2019-2024 | Synthroid |
| Insulet Corporation | $383.27 | 2019-2025 | Omnipod |
| Alexion Pharmaceuticals, INC. | $354.05 | 2019-2025 | Strensiq |
| Mannkind Corporation | $328.47 | 2019-2023 | Afrezza |
| Radius Health, INC. | $320.51 | 2019-2025 | Tymlos |
| Amneal Pharmaceuticals LLC | $256.40 | 2019-2025 | Unithroid |
| Antares Pharma, INC. | $214.70 | 2019-2023 | Tlando, Nocdurna, Xyosted |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyuba Belitsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.